Index

absence of benefit, defining, 305–6
ABT-418, in attention-deficit hyperactivity disorder treatment, 278
acetylcholine breakdown, 294
half-life prolongation, 293
acetylcholinesterase, inhibition, 294, 295
activities of daily living (ADL), 306
assessment, 301
acute bipolar depression, 22
pharmacotherapy, first-line, 28–35
studies, 34, 35
acute delirium, 298
acute mania, 22
pharmacotherapy, first-line, 23–8
polypharmacy, 28
studies, 24, 28
bias, 27
switch rates, 33
ADAS see Alzheimer’s Disease Assessment Scale (ADAS)
Adderall in attention-deficit hyperactivity disorder treatment, 257
dosage issues, 258
Adderall XR in attention-deficit hyperactivity disorder treatment, 267
dosage issues, 267
ADHD see attention-deficit hyperactivity disorder (ADHD)
adherence in major depressive disorder treatment, 12
in social anxiety disorder treatment, 157
ADL see activities of daily living (ADL)
α-adrenergic agents, in attention-deficit hyperactivity disorder treatment, 273–8
β-adrenergic blocking agents, in panic disorder treatment, 107
α₂-adrenergic receptor agonists, in panic disorder treatment, 107
adults, attention-deficit hyperactivity disorder, 236–7
agoraphobia avoidance strategies, 107
definition, 105
differential diagnosis, 106
pharmacotherapy combined, 116
meta-analysis, 112
prevalence, 106
akathisia, 72
alcohol, and panic disorder, 106
alcohol abuse, and social anxiety disorder, 154
alprazolam, 125
in panic disorder treatment, 108, 109–12
and posttraumatic stress disorder, 129
in social anxiety disorder treatment, 140, 145, 154
versus flesinoxan, 95–6
versus phentolamine, 140
versus pregabalin, 94–5
Alzheimer’s disease with brain ischemia, 291
with cerebrovascular disease, 291
clinical trials, issues, 291–2
and dementia, 290
and depression, 292
diagnosis accuracy, 293
clinical versus autopsy, 291–2
etiology, 312
and folate deficiency, 313
interventions, 292
types of, 292
observational studies, 311–13
pathology, 290
pharmacotherapy
assessment, 293
drug holidays, 306
duration, 306–7
ethical issues, 298, 306, 307
evidence-based, 290–314
first-line, 293–306
outcomes measures, 301
prescribing issues, 292
prevalence, 290
and senile dementia compared, 290
smoking and, 293–4
treatment-resistant, pharmaco therapy, 313–14
use of term, 290
Alzheimer’s Disease Assessment Scale (ADAS), 306
American Psychiatric Association (APA), eating
American Psychiatric Association (APA), eating
Anxiety Disorders (DSM-IV), 293
anorexia nervosa (AN)
and body shape, 207
comorbidity, 206
diagnostic criteria, 204
pharmacotherapy, 207–9
efficacy studies, 205
long-term, 243
methodological issues, 239
response predictors, 242–3
short-term efficacy, 240–1
prevalence, 205
psychopharmacology, 211
study resources, 205
symptoms, 204
treatment guidelines, 243
and weight gain, 207
and zinc deficiency, 216
see also bulimia nervosa (BN)
anticoricals
in acute bipolar depression treatment, 30–1
in acute mania treatment, 23–5
in bipolar disorder prophylaxis, 38–9, 43
in bulimia nervosa treatment, 228
in rapid-cycling bipolar disorder treatment, 43
anti-dementia interventions, methodological
developments, 301
antidepressants
in acute bipolar depression treatment, 32–3, 35
and Alzheimer’s disease, 292
in anorexia nervosa treatment, 240–1
anti-dementia activity, 292
in bipolar disorder prophylaxis, 41
development, 1, 2
future trends, 17
dosage issues, 114
drug augmentation, 14–15, 188
drug interactions, 322–3
dosage, 322–3
dual-action, 2, 5–6
effectiveness, 5–6
early, 1
effectiveness, 2, 12, 17
age differences, 10
efficacy, 3, 113–14
in maintenance treatment, 11
mechanisms, 271
meta-analyses, 3, 4, 112
metabolism, 274
non-response, 12–13, 16
non-serotonergic, 168–9
Analyzing, 312
and folate deficiency, 313
interventions, 292
types of, 292
observational studies, 311–13
pathology, 290
pharmacotherapy
assessment, 293
drug holidays, 306
duration, 306–7
ethical issues, 298, 306, 307
evidence-based, 290–314
first-line, 293–306
outcomes measures, 301
prescribing issues, 292
prevalence, 290
and senile dementia compared, 290
smoking and, 293–4
treatment-resistant, pharmacotherapy, 313–14
use of term, 290
Alzheimer’s Disease Assessment Scale (ADAS), 306
American Psychiatric Association (APA), eating
American Psychiatric Association (APA), eating
Anxiety Disorders (DSM-IV), 293
anorexia nervosa (AN)
and body shape, 207
comorbidity, 206
diagnostic criteria, 204
pharmacotherapy, 207–9
efficacy studies, 205
long-term, 243
methodological issues, 239
response predictors, 242–3
short-term efficacy, 240–1
prevalence, 205
psychopharmacology, 211
study resources, 205
symptoms, 204
treatment guidelines, 243
and weight gain, 207
and zinc deficiency, 216
see also bulimia nervosa (BN)
anticoricals
in acute bipolar depression treatment, 30–1
in acute mania treatment, 23–5
in bipolar disorder prophylaxis, 38–9, 43
in bulimia nervosa treatment, 228
in rapid-cycling bipolar disorder treatment, 43
anti-dementia interventions, methodological
developments, 301
antidepressants
in acute bipolar depression treatment, 32–3, 35
and Alzheimer’s disease, 292
in anorexia nervosa treatment, 240–1
anti-dementia activity, 292
in bipolar disorder prophylaxis, 41
development, 1, 2
future trends, 17
dosage issues, 114
drug augmentation, 14–15, 188
drug interactions, 322–3
dual-action, 2, 5–6
effectiveness, 5–6
early, 1
effectiveness, 2, 12, 17
age differences, 10
efficacy, 3, 113–14
in maintenance treatment, 11
mechanisms, 271
meta-analyses, 3, 4, 112
metabolism, 274
non-response, 12–13, 16
non-serotonergic, 168–9
Index

antidepressants (cont.)
in panic disorder treatment, 107, 108–10, 112–14
in posttraumatic stress disorder treatment, 126–7, 130
in rapid-cycling bipolar disorder treatment, 42–3
response, 2
age differences, 10
sex differences, 9
selection criteria, 3
serotonergic versus non-serotonergic, 168–9
side-effects, 109
switching, 13
treatment duration issues, 10–12
trials, 2, 3
comparative, 8–9
triple-action, 2, 5–6
effectiveness, 5–6
versus benzodiazepines, 109–10, 111
see also monoamine oxidase inhibitors (MAOIs); selective serotonin reuptake inhibitors (SSRIs); serotonin-norepinephrine (noradrenaline) reuptake inhibitors (SNRIs); serotonin reuptake inhibitors (SRIs); tricyclic antidepressants (TCAs)
anti-inflammatory drugs, in Alzheimer’s disease treatment, 312–13
antipsychotics
in anorexia nervosa treatment, 207–9
in attention-deficit hyperactivity disorder treatment, 277
atypical
advantages, 78
comparisons, 75
versus conventional, 74–5
dosage issues, 75
drug augmentation, 190–1
drug interactions, 322
evaluation, 56
in panic disorder treatment, 107
in posttraumatic stress disorder treatment, 129
in schizophrenia treatment, 56
side-effects, 75
trials, 56, 76
anxiety disorders
comorbidity, 8
versus panic disorder, 106
see also generalized anxiety disorder (GAD); social anxiety disorder
anxiolytics, 89
drug augmentation, 188
APA (American Psychiatric Association), 243
appetite, modulation, 214
appetite enhancers, in anorexia nervosa treatment, 214–16, 217
Aripiprazole, see donepezil
arrhythmias, risk factors, 78
ARTIST trial, 4
atenolol, 148
in social anxiety disorder treatment, 139–41
versus phenelzine, 140
atomoxetine
in attention-deficit hyperactivity disorder treatment, 274–5
efficacy, 275
side-effects, 275
versus placebo, 274–5
attention-deficit hyperactivity disorder (ADHD) adult, 246–7
behavior therapy, 278–9
costs, 255
diagnostic criteria, 255
drug holidays, 265
educational remediation, 258
etiology, 255–6
follow-up studies, 256
genetic bases, 256
morbidly, 255
and nicotinic dysregulation, 277–8
pathophysiology, 255–6
pharmacotherapy
cognitive effects, 258
drug classes, 259, 260, 261, 262, 263
duration, 278–9
evidence-based, 255–79
first-line, 257–75
prevalence, 255
prognosis, 256
and smoking risk, 277
and substance abuse, 264
subtypes, 255
symptoms, 255
augmentation (drug) see drug augmentation
axis II personality disorder, comorbidity, 8
INDEX

BED see binge-eating disorder (BED)
behaviour therapy
in attention-deficit hyperactivity disorder
treatment, 278–9
in panic disorder treatment, 107
see also cognitive-behavioral therapy (CBT)
benzodiazepines, 27, 89
and generalized anxiety disorder, 89, 96–7, 98
in generalized anxiety disorder treatment, 94
limitations, 99
meta-analyses, 112
in non-generalized social anxiety disorder
treatment, 159
and panic disorder, 106
in panic disorder treatment, 107, 108, 109–10
disadvantages, 113
and posttraumatic stress disorder, 129
prescribing issues, 94
with selective serotonin reuptake inhibitors,
110, 114, 115
side-effects, 94, 113
in social anxiety disorder treatment, 145, 148,
151, 153–4
with tricyclic antidepressants, 115
versus antidepressants, 109–10, 111
versus buspirone, 95
benztropine, 66, 74
Berkson’s bias, 291
beta-amyloid, accumulation reduction, 294
beta-blockers
in attention-deficit hyperactivity disorder
treatment, 277
drug interactions, 304
in non-generalized social anxiety disorder
treatment, 159
in social anxiety disorder treatment, 146
bethanechol, 214
bias issues, negative studies, 27
bilobalide, 310
binge-eating disorder (BED)
combined pharmacological/psychological
treatment, 242
diagnostic criteria, 204–5
pharmacotherapy, 234–9
efficacy studies, 205
long-term, 242–3
methodological issues, 240
short-term efficacy, 241
prevalence, 205
study resources, 205
symptoms, 204–5
treatment guidelines, 244
bioavailability (drug) see drug bioavailability
bipolar disorder
comorbidity, 22
diagnosis, 12
pharmacotherapy, evidence-based, 22–44
polypharmacy, 43–4
prevalence, 22
prophylaxis
pharmacotherapy, 28, 35–44
studies, 36, 43–4
rapid-cycling, 43–2
recurrence, 11
risk factors, 22
study resources, 22–3
type I, 33, 42
type II, 33, 42
see also acute bipolar depression; acute mania;
mania
blood-brain barrier, 294, 303, 329
blood clotting, 310
blood pressure
stimulant effects, 263–4
see also hypertension; hypotension
BN see bulimia nervosa (BN)
body shape, and anorexia nervosa, 207
body weight
and eating disorders, 206
regulatory mechanisms, 206
see also weight gain
bone mineral density, 77
bradycardia, 304
brain changes, and Alzheimer’s disease, 290
brain ischemia, 291
with Alzheimer’s disease, 291
diagnosis, 291
Brief Social Phobia Scale (BSPS), 146
brotizolam, 2, 125
in bulimia nervosa treatment, 222
in posttraumatic stress disorder treatment,
125
in social anxiety disorder treatment, 142, 152,
155
versus placebo, 142
bromazepam
in social anxiety disorder treatment, 145, 154
versus hydroxyzine, 96
BSPS (Brief Social Phobia Scale), 146
© Cambridge University Press  www.cambridge.org
bulimia nervosa (BN)
  cognitive-behavioral therapy, short-term efficacy, 232–3
  combined pharmacological/psychological treatment, 230–3, 241–2
  meta-analyses, 231–4
  short-term efficacy, 232–3
  comorbidity, 206
  diagnostic criteria, 204
  future research, 244
  improvement, 233
  meta-analyses, 231–4
  completion rates, 231–2
  effect size, 232
  exclusion criteria, 231–2
  inclusion rates, 231–2
  pharmacotherapy, 219–30
  efficacy studies, 205
  long-term, 242–3
  long-term efficacy, 234
  meta-analyses, 231–4
  methodological issues, 239–40
  response predictors, 242
  short-term, 232
  short-term efficacy, 232–3, 241
  versus psychotherapy, 230–1
  prevalence, 205
  psychotherapy, 230–4
  recovery rate, 233
  study resources, 205
  subtypes, 240
  symptoms, 204, 239
  post-treatment, 233–4
  treatment guidelines, 243–4
  see also anorexia nervosa (AN)
  bupropion, 2
  in acute bipolar depression treatment, 32–3
  in attention-deficit hyperactivity disorder treatment, 269, 272–3
  in attention-deficit hyperactivity disorder prophylaxis, 41
  in bulimia nervosa treatment, 228, 229
  effectiveness, 5, 15
  pharmacology, 272–3
  side-effects, 273
  buspirone, 148
  in attention-deficit hyperactivity disorder treatment, 277
  drug augmentation, 189
  efficacy, 96, 99
  in generalized anxiety disorder treatment, 95, 158
  in posttraumatic stress disorder treatment, 129
  in social anxiety disorder treatment, 146
  versus venlafaxine, 93–4
  butyrylcholinesterase, inhibition, 294
  caffeine, and panic disorder, 106
  calcium channel blockers, 27
  calcium channels, voltage-gated, 94
  cannabinoids, 214–16
  and panic disorder, 106
  CAPS (Clinician Administered PTSD Scale), 121–2
  capsulotomy, 191–2
  carbamazeipine, 23
  in acute bipolar depression treatment, 29–30
  in acute mania treatment, 25
  in attention-deficit hyperactivity disorder treatment, 277
  in bipolar disorder prophylaxis, 38, 43–4
  in bulimia nervosa treatment, 228
  in panic disorder treatment, 107
  in posttraumatic stress disorder treatment, 128–9
  cardiac conduction block, 304
  cardiovascular dysfunctions, stimulant-induced, 263–4
  cardiovascular system, tricyclic antidepressant effects, 305
  CGI
  see Clinical Global Impression (CGI);
  Conners’ Global Index
  ChEIs
  see cholinesterase inhibitors (ChEIs)
  Child Health Questionnaire, 275
  children, sudden death, 276–7
  children, sudden death, 276–7
  chi-square test, 148, 150
  chloridiazepoxide, versus propranolol, 96
  2′-chlorodesmethyldiazepam, versus paroxetine, 91
  m-chlorophenylpiperazine, 89
chlorpromazine, 23, 25, 26, 74
in anorexia nervosa treatment, 207
and electroconvulsive therapy, 28
side-effects, 207
versus olanzapine, 73
versus quetiapine, 64–5
cholecytokinin, 89
cholinergic drugs
in Alzheimer’s disease treatment, 293
cost-effectiveness, 304
cholinergic system, defects, 295
cholinesterase inhibitors (ChEIs), 292
in Alzheimer’s disease treatment, 293–306
clinical issues, 303
in clinical practice, 305
cost-effectiveness, 304–5
in dementia with Lewy bodies treatment, 295
drug holidays, 306
issues, 306–7
drug interactions, 303–4
drug-switching issues, 305
efficiency, 305
mechanisms, 294–5
patient differences, 293–301
selection criteria, 303–4
side-effects, 301–2
in treatment-resistant Alzheimer’s disease
treatment, 313
types of, 294
in vascular dementia treatment, 295–8
CIBIC-plus see Clinician’s Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus)
cingulotomy, 191–2
cisapride, 214, 274
in anorexia nervosa treatment, 214
side-effects, 214
citalopram, 1, 274
in anorexia nervosa treatment, 211
dose-response relationships, 179–80
drug-switching, 187–8
in generalized anxiety disorder treatment, 90
in obsessive-compulsive disorder treatment, 172, 175–6
in panic disorder treatment, 109
in posttraumatic stress disorder treatment, 126
versus escitalopram, 90
versus placebo, 172
Clinical Global Impression (CGI), 139, 158, 183
benzodiazepine studies, 145
brofaromine studies, 142
fluoxetine studies, 171
fluvoxamine studies, 169, 226
moclobemide studies, 141
paroxetine studies, 143, 156
risperidone studies, 191
sertraline studies, 144, 175
treatment-response studies, 187
venlafaxine studies, 145
Clinical Global Severity, 237
Clinician Administered PTSD Scale (CAPS), 121–2
Clinician’s Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus)
applications, 300–1
overview, 300
clozapine
in anorexia nervosa treatment, 209
dosage issues, 178
dose-response relationships, 180
drug augmentation, 188–9
drug switching, 187–8
noradrenergic metabolites, 169
in obsessive-compulsive disorder treatment, 166–7, 174–5
with depression, 167–8
long-term, 183–4
without depression, 167
in panic disorder treatment, 109, 111–12
relapse rates, 184
side-effects, 176–8
versus clorgyline, 167, 168
versus desipramine, 168, 181
versus exposure therapy, 167
versus imipramine, 168
versus nortriptyline, 168
versus paroxetine, 171
versus selective serotonin reuptake inhibitors, 173–4, 176, 177, 181
versus venlafaxine, 182
withdrawal effects, 183–4
Clomipramine Collaborative Group, 167
clozapine
in acute mania treatment, 27
and bipolar disorder prophylaxis, 41
drug augmentation, 189–90
in panic disorder treatment, 108, 109–10
in social anxiety disorder treatment, 145, 149, 152, 154, 158
clonidine
in attention-deficit hyperactivity disorder treatment, 275–8
dosage issues, 275–6
effects on noradrenergic system, 89
efficacy, 276
indications, 275
mechanisms, 275
with methylphenidate, 276–7
in panic disorder treatment, 107
in posttraumatic stress disorder treatment, 129
side-effects, 276
versus methylphenidate, 276
clorgyline, versus clomipramine, 167, 168
clozapine, 191
in acute mania treatment, 26
in bipolar disorder prophylaxis, 40–1
drug clearance, 326–7
effects on noradrenergic system, 89
in schizophrenia treatment, 72, 74
side-effects, 27, 59–60
versus risperidone, 59, 72–3
cocaine, and panic disorder, 106
Cochrane Collaboration
database, 90, 122
goals, 293
studies, 4–5, 7
imipramine, 96
limitations, 7
lithium, 35
rivastigmine, 303
Cochrane Dementia and Cognitive Improvement Group, 293
cognition, as outcomes measure, 301
cognitive-behavioral therapy (CBT)
in bulimia nervosa treatment, 230–1, 241–2
meta-analyses, 232–3
short-term efficacy, 232–3
with diazepam, 98
in generalized anxiety disorder treatment, 98
in obsessive-compulsive disorder treatment, 178
in panic disorder treatment, 107, 110, 111, 114
in social anxiety disorder treatment, 140–1
in treatment-resistant social anxiety disorder, 158
versus phenergan, 141, 153
versus risperidone, 71
cognitive therapy (CT), in panic disorder treatment, 107, 111
Cohen’s d, 112, 148, 149, 150, 232
comorbidity, major depressive disorder, 6–10
Comprehensive Psychopathological Rating Scale (CPRS), 165
Obsessive-Compulsive Subscale, 167
Concerta
in attention-deficit hyperactivity disorder treatment, 265–6
efficacy, 265–6
mechanisms, 265
Conners’ ADHD/DSM-IV Scales, 267
Conners’ Global Index, 266
Scale for Teachers and Parents, 267
corticosteroids releasing factor, 89
and posttraumatic stress disorder, 122
cortisol, and posttraumatic stress disorder, 122
CPRS see Comprehensive Psychopathological Rating Scale (CPRS)
cyproheptadine, in posttraumatic stress disorder treatment, 129
CT see cognitive therapy (CT)
cytochrome P450 enzymes see P450 enzymes
cytoskeleton, in anorexia nervosa treatment, 209–11, 214
in posttraumatic stress disorder treatment, 129
cytoskeleton P450 system, 274, 324
see also P450 enzymes
DAD (Disability Assessment for Dementia) scale, 301
Davidson Trauma Scale (DTS), 121–2
deep brain stimulation, 192
dementia
agd of onset, 290
cognition, as outcomes measure, 301
cognitive-behavioral therapy (CBT)
in bulimia nervosa treatment, 230–1, 241–2
meta-analyses, 232–3
short-term efficacy, 232–3
with diazepam, 98
in generalized anxiety disorder treatment, 98
in obsessive-compulsive disorder treatment, 178
in panic disorder treatment, 107, 110, 111, 114
in social anxiety disorder treatment, 140–1
in treatment-resistant social anxiety disorder, 158
versus phenergan, 141, 153
versus risperidone, 71
cognitive therapy (CT), in panic disorder treatment, 107, 111
Cohen’s d, 112, 148, 149, 150, 232
comorbidity, major depressive disorder, 6–10
© Cambridge University Press
www.cambridge.org
monoamine hypothesis, 1
with obsessive-compulsive disorder, pharmacotherapy, 167–8, 181
and social anxiety disorder, 157
subtypes, 6–10
see also acute bipolar depression; bipolar disorder; major depressive disorder (MDD)
desipramine, 33, 125
in attention-deficit hyperactivity disorder treatment, 269–70, 271
in bulimia nervosa treatment, 219, 230
drug augmentation, 14–15
in posttraumatic stress disorder treatment, 125
versus clomipramine, 168, 181
versus cognitive-behavioral therapy, 230–1
versus fluvoxamine, 181
versus sertraline, 181
dexamethasone suppression test, 206
Dexedrine or dextroamfetamine
dexamylphenidate activity, 267
in attention-deficit hyperactivity disorder treatment, 268
drug development, 267–8
dextroamphetamine in attention-deficit hyperactivity disorder treatment, 257
dosage issues, 258
diabetes mellitus, 27, 76–7
Diagnostic and Statistical Manual of Mental Disorders (DSM)
binge-eating disorder, 204–5
dementia, 308
DSM-III, social anxiety disorder, 137, 149–50
DSM-III-R
generalized anxiety disorder, 88
social anxiety disorder, 137, 139, 149–50
DSM-IV
anorexia nervosa, 204
attention-deficit hyperactivity disorder, 255
bulimia nervosa, 204, 240
depressive subtypes, 6
generalized anxiety disorder, 88, 137
panic disorder, 105, 106
posttraumatic stress disorder, 121
social anxiety disorder, 137, 143, 149–50
diuretics, 89
with cognitive-behavioral therapy, 98
in panic disorder treatment, 108
versus bupropion, 95
versus imipramine, 95
versus tetrahydroamcinolone, 214–16
versus venlafaxine, 93
Disability Assessment for Dementia (DAD) scale, 301
displacement interactions, 325, 330
Dissertation Abstract, 147
DMI see desipramine
domperidone, 214
donepezil in Alzheimer’s disease treatment, 294, 297,
298–300
benefits, 298
risk factors, 299
cost-effectiveness, 304–5
dosage issues, 295, 303
drug holidays, 307
drug interactions, 304
titration schemes, 302
trials, 301
in vascular dementia treatment, 295–8
versus galantamine, 302, 303
versus placebo, 301
versus rivastigmine, 302, 303
1-dopa, 278
dopamine, 1, 271
dopamine agonists, 278
in acute bipolar depression treatment, 35
dopamine receptor genes, and attention-deficit hyperactivity disorder, 256
dopaminergic neurotransmission, 257
dropout, 78
drug absorption and food, 329
mechanisms, 327–9
drug administration, oral, 327
drug augmentation antidpressants, 14–15
strategies, 15, 16
for treatment-resistant major depressive disorder, 13–15
for treatment-resistant obsessive-compulsive disorder, 188, 190–1
for treatment-resistant posttraumatic stress disorder, 128
for treatment-resistant social anxiety disorder, 158
drug bioavailability altered, 327–9
determinants, 329
drug clearance
 definition, 325
and drug interactions, 324
elimination half-life, 324–5
hepatic, 323–6, 330–1
mechanisms, 325
organ clearance model, 325
renal, 325
roles, 324–7
drug interactions, 320–37
antidepressants, 322–3
antipsychotics, 322
beta-blockers, 304
cholinesterase inhibitors, 303–4
classification, 323–4
issues, 321
costs, 320
daily exposure, 320
donepezil, 304
and drug clearance, 324
enzyme induction, 331–5
enzyme inhibition, 335–6
galantamine, 304
historical background, 321–3
in vivo prediction, 336–7
monooamine oxidase inhibitors, 222, 322
mortality, 320
pharmacological, 323
pharmacokinetic, 321–2, 323–4
mechanisms, 327–36
protein-binding in, 327
psychostimulant drugs, 320–1, 332
rivastigmine, 304
safety regulations, 322
selective serotonin reuptake inhibitors, 322–3
drug metabolism, 328
in liver, 331
drug-protein binding, reversibility, 330
DSM see Diagnostic and Statistical Manual of
Mental Disorders (DSM)
DTS (Davidson Trauma Scale), 121–2
duloxetine, 2
Eating Attitudes Test, 226
Eating Disorder Examination (EDE), 237
Eating Disorder Inventory-2 (EDI-2), 226
olanzapine studies, 209
eating disorders (EDs)
as affect disorders, 206
and body weight, 206
combined pharmacological/psychological
treatment, 241–2
effects, 205
etiology, 204
future research, 244–5
long-term issues, 205
mortality rates, 205
pharmacotherapy, 206–7
classification, 205–6
safety regulations, 205
evidence-based, 204–45
long-term, 242–3
methodological issues, 239–40
response predictors, 242
short-term efficacy, 240–1
prevalence, 204, 205
study resources, 205
treatment guidelines, 243–4
see also anorexia nervosa (AN); binge-eating
disorder (BED); bulimia nervosa (BN)
ECA (Epidemiological Catchment Area), 22, 137
ECT see electroconvulsive therapy (ECT)
EDE (Eating Disorder Examination), 237
EDE-2 see Eating Disorder Inventory-2 (EDI-2)
EDs see eating disorders (EDs)
effect size
in bulimia nervosa meta-analyses, 232
homogeneity versus heterogeneity, 150
measures, 148, 149, 150
adjusted, 151–2
observer-rated, 150
Effexor see venlafaxine
ECG see Electrocardiogram
activity, 310
in Alzheimer’s disease treatment, 100–11
applications, 310
side-effects, 310
elderly
antidepressants, effectiveness studies, 10
orthostatic hypotension, 7
electroconvulsive therapy (ECT), 191
in acute bipolar depression treatment, 32
in acute mania treatment, 28
in bipolar disorder prophylaxis, 42
evaluation see drug clearance
elimination half-life, 324–5
EMBASE, 90
searches, 186
electroconvulsive
drug interactions, 331–5
mechanisms, 331–5
temporal issues, 335
use of term, 331
enzyme inhibition
clinical significance, 336
drug interactions, 335–6
mechanisms, 335–6
temporal issues, 336
enzymes
hepatic, 326
phase I, 331
phase II, 331
see also P450 enzymes
Epidemiological Catchment Area (ECA) studies, 22, 137
EPS see extrapyramidal symptoms (EPS)
eslicopram, 1
efficacy, 96, 99
in generalized anxiety disorder treatment, 90–1
treatment duration, 97–8
in panic disorder treatment, 109
estrogen, 312
trials, 312
ethical issues, 298, 306, 307
European Agency for the Evaluation of Medical Products, 308
European Medicines Evaluation Agency, 301
evidence-based pharmacotherapy of major depressive disorder, 1–17
Exelon see rivastigmine
Expert Consensus Panel for OCD, 178
Guidelines, 180, 186, 188
exposure therapy
versus clomipramine, 167
versus sertraline, 144
exposure in vivo, in panic disorder treatment, 107, 111
extrapyramidal symptoms (EPS), 26
antipsychotic-induced, 74–5
and atypical antipsychotics, 78
olanzapine-induced, 62
reduction strategies, 74
risperidone-induced, 58, 59, 60
Fear Questionnaire (FQ), 140
fenfluramine, 278
d-fenfluramine, in binge-eating disorder treatment, 237–9
fixed effects model, versus random effects model, 150
flavonoids, 310, 329
flexoxan, in generalized anxiety disorder treatment, 95–6
versus placebo, 95–6
flunitrazepam, 1, 125
in acute bipolar depression treatment, 32
in anorexia nervosa treatment, 211
in attention-deficit hyperactivity disorder treatment, 269, 273
axis II personality disorder studies, 8
in binge-eating disorder treatment, 237
in bipolar disorder prophylaxis, 41
in bulimia nervosa treatment, 222–6, 230
dose–response relationships, 179, 180, 186–7
drug augmentation, 14–15
drug interactions, 322–3
effectiveness, 4, 5
efficacy, 4
in generalized anxiety disorder treatment, 91
non-response, 13
in obsessive-compulsive disorder treatment, 170–1, 173–6
long-term, 183, 186–7
P450 enzyme inhibition, 337
in panic disorder treatment, 109
in posttraumatic stress disorder treatment, 125–6, 127–8
relapse rates, 184
response, sex differences, 9
versus clomipramine, 174–5
versus phendalfine, 168, 171
versus placebo, 170–1
fluoxetine, 1
versus amisulpride, 69
fluvoxamine, 1
in binge-eating disorder treatment, 234–7
in bulimia nervosa treatment, 222, 226–7
dosage issues, 178
in generalized anxiety disorder treatment, 91
in obsessive-compulsive disorder treatment, 169–70, 173–6, 182
in panic disorder treatment, 109, 111–12
in posttraumatic stress disorder treatment, 126
in social anxiety disorder treatment, 143–4, 148
versus clomipramine, 174–5
versus desipramine, 181
versus maprotiline, 109
versus placebo, 143–4, 169–70, 226–7
Focalin see dexmethylphenidate
folate deficiency, and dementia, 313
food, and drug absorption, 329
FQ (Fear Questionnaire), 140
Freud, Sigmund, 314
frontostriatal dysfunction, and attention-deficit hyperactivity disorder, 255, 256, 257
GABA (gamma-aminobutyric acid), 89, 94, 311
gabapentin, 25
in acute bipolar depression treatment, 30–1
in bipolar disorder prophylaxis, 38
in social anxiety disorder treatment, 146, 152, 155, 158
GAD see generalized anxiety disorder (GAD)
galantamine
in Alzheimer’s disease treatment, 294, 297, 298
benefits, 298
risk factors, 299
cost-effectiveness, 304–5
dosage issues, 295
drug interactions, 304
titration schemes, 302, 305
trials, 301
in vascular dementia treatment, 295–8
versus donepezil, 302, 303
versus placebo, 301
gamma-aminobutyric acid/benzodiazepine receptor system, and generalized anxiety disorder, 89
gastric motility, abnormal, 211–14
generalized anxiety disorder (GAD)
cognitive-behavioral therapy, 98
comorbidity, 88–9, 99
diagnostic criteria, 137
neurotransmitter disturbances, 89–90
pathophysiology, 89
pharmacotherapy
evidence-based, 88–99
first-line, 90–7
with psychotherapy, 98
treatment duration, 97–8
prevalence, 88, 98–9
saccadic eye movement velocity, 89
study resources, 90
symptoms, 88
treatment-resistant
drug augmentation, 158
pharmacotherapy, 98
see also non-generalized anxiety disorder
genetics, and attention-deficit hyperactivity disorder, 256
ginkgo biloba (maidenhair tree), 313
active compounds, 310
in Alzheimer’s disease treatment, 310–11
ginkgolides, 310
Glass’s delta, 148
gliosis, 309
glucocorticoid receptors, and posttraumatic stress disorder, 122
L-glutamate, functions, 307–8
glutaminergic system, modulation, 307–8
P-glycoprotein (P-gp)
activity, 329
and drug bioavailability, 329
in drug metabolism, 328
localization, 329
substrates, 336
grapefruit juice, and drug bioavailability, 329
growth deficits, stimulant-induced, 284–5
guanfacine, 276
in attention-deficit hyperactivity disorder treatment, 275–6, 278
Hachinski score, 308
haloperidol
in acute mania treatment, 26
as antipsychotic comparator, 56, 74
drug augmentation, 190
in schizoaffective treatment, 74
versus amisulpride, 69
versus aripiprazole, 70, 71
versus clozapine, 73–4
versus olanzapine, 62–3, 72, 73–4
versus quetiapine, 64, 73
versus risperidone, 58, 60, 72, 73–4
versus sertindole, 67–8
versus ziprasidone, 66
Hamilton Anxiety Rating Scale (HAM-A), 91
citalopram studies, 90
paroxetine studies, 91–2
sertraline studies, 92–3
Hamilton Depression Rating Scale (HAM-D), 4, 8, 9, 13, 14
citalopram studies, 90
clomipramine studies, 167
olanzapine studies, 209
valproate studies, 30
Hederg’s g, 151
hepatic enzymes, rules, 326
hepatic toxins, drug metabolism, 326
herbal drugs, 320
hippocampal region, reduced volume, 122
hormone replacement therapy (HRT)
in Alzheimer’s disease treatment, 312
benefits, 312
HPA axis see hypothalamus–pituitary–adrenal (HPA) axis
HRT see hormone replacement therapy (HRT)
5-HT see serotonin
5-hydroxyindoleacetic acid, 89
5-hydroxytryptamine (5-HT) see serotonin
5-hydroxytryptamine receptor agonists, in
generalized anxiety disorder treatment, 95–6
hydroxyzine
efficacy, 96
in generalized anxiety disorder treatment, 96
versus placebo, 96
hyperhomocysteinemia, 313
hyperlipidemia, 313
hyperprolactinemia
antipsychotic-induced, 77
risperidone-induced, 59
hypertension
and clonidine, 275
withdrawal, 276
hypertriglyceridemia, 76–7
hypoglycemia, 106
hypogonadism, 77
hypomania, prevalence, 22
hypothalamus
medioventral, 206
hypothalamus–pituitary–adrenal (HPA) axis, 122
negative feedback inhibition, 122
ICD (International Classification of Diseases), 88–9
idazoxan, 33
imipramine, 1
in acute bipolar depression treatment, 29
in attention-deficit hyperactivity disorder
treatment, 269, 271
axis II personality disorder studies, 8
in binge-eating disorder treatment, 234, 238
in bipolar disorder prophylaxis, 41
in bulimia nervosa treatment, 219, 230
drug-switching studies, 13
effectiveness, 5
efficacy, 96
in generalized anxiety disorder treatment, 95
in panic disorder treatment, 109–10, 111–12
treatment duration, 114–15
in posttraumatic stress disorder treatment, 125
response, sex differences, 9
trials, 8–9
versus clomipramine, 168
versus paroxetine, 91
versus placebo, 95, 96
indomethacin, in Alzheimer’s disease treatment,
312–13
inositol, 125
and posttraumatic stress disorder, 129
in treatment-resistant obsessive-compulsive disorder, 191
intent-to-treat (ITT) analysis
in panic disorder studies, 118
in social anxiety disorder studies, 142, 144, 146, 152, 156
International Classification of Diseases (ICD), 88–9
ICD-10, generalized anxiety disorder, 88–9
interpersonal psychotherapy (IPT), in
bulimia nervosa treatment, 231
ischemic stroke, 307
isoniazid, 1
ketoadiposis, diabetic, 26
kidneys, drug clearance, 325
lamotrigine, 25, 125
in acute bipolar depression treatment, 30
in bipolar disorder prophylaxis, 38, 42
in posttraumatic stress disorder treatment, 128
leukoaraiosis, 291
levetiracetam, 31
Lexapro see escitalopram
Lithotriptor Social Anxiety Scale (LSAS), 146, 149
benzodiazepine studies, 145
brofaromine studies, 142
fluvoxamine studies, 143
in meta-analyses, 151
mockobemide studies, 141
paroxetine studies, 143
sertraline studies, 144
social avoidance subscale, 140, 141
venlafaxine studies, 145
lithium
in acute bipolar depression treatment, 28, 35
in acute mania treatment, 23, 28
in anorexia nervosa treatment, 211
in bipolar disorder prophylaxis, 35–8, 43
in bulimia nervosa treatment, 227–8
drug augmentation, 13, 14–15, 16, 189
drug interactions, 322
mortality prophylaxis, 37–8
in panic disorder treatment, 107
in posttraumatic stress disorder treatment, 128–9
side-effects, 211
suicide prophylaxis, 37–8
trials, 23
versus placebo, 28
lithium carbonate, 13
liver
drug clearance, 325–6, 330–1
drug metabolism, 331
function, and magnesium pemoline, 264
LSAS see Liebowitz Social Anxiety Scale (LSAS)
Luvox see fluvoxamine
lymphocytes, binding, 89
MADRS (Montgomery Asberg Depression Rating Scale), 31
magnesium pemoline
in attention-deficit hyperactivity disorder treatment, 257
dosage issues, 258
side-effects, 264
magnetic resonance imaging (MRI), attention-deficit hyperactivity disorder studies, 255–6
maintenance of effect assessment
continuation treatment design, 97
relapse-prevention design, 97
maintenance treatment
antidepressants in, 11
individual differences, 11
obsessive-compulsive disorder, 186
placebo studies, 11–12, 16
posttraumatic stress disorder, 127–8
studies, 16–17
major depressive disorder (MDD)
age differences, 10
atypical, comparative drug trials, 8–9
comorbidity, 8–10
anxiety disorders, 8
axis II personality disorder, 8
medical, 7–8
demographics, 6–10, 15–16
lifetime risk, 1
maintenance treatment, 11, 16
pharmacotherapy
adherence issues, 12
drug selection criteria, 3
duration, 10–12
evidence-based, 1–17
first-line, 3–10, 15
non-response, 16
trials, 2, 3
prevalence, 1
recurrence, 10
relapse
prediction, 10–11
risk, 12
sex differences, 9
subtypes, 8–9
treatment-resistant, drug augmentation, 13–15
pharmacotherapy, 12–15
mania
prevalence, 22
study bias, 27
see also acute mania
MAOIs see monoamine oxidase inhibitors (MAOIs)
maprotiline, versus fluvoxamine, 109
marijuana, 264
Maudsley Obsessive-Compulsive Inventory, 170
MDD see major depressive disorder (MDD)
medline, 2, 90
searches, 22, 105, 122, 139, 166
melancholia, 206
menopause
in Alzheimer’s disease treatment, 307–8
early studies, 308
mechanisms, 307–8
versus placebo, 308
in treatment-resistant Alzheimer’s disease treatment, 313
meta-analyses
advantages, 2, 146
limitations, 173
overview, 146–7
Meta-Data-CE, in attention-deficit hyperactivity disorder treatment, 266
3-methoxy-4-hydroxyphenylglycol, 89
N-methyl-D-aspartate (NMDA), 307–8
methylphenidate
in attention-deficit hyperactivity disorder
treatment, 257, 264, 266
with clonidine, 276–7
controlled delivery, 265, 266
dosage issues, 258
isomers, 267
stereoselectivity, 267
versus clonidine, 276
see also dexmethylphenidate
methylphenidate immediate release (MPH IR)
in attention-deficit hyperactivity disorder
treatment, 265–6
dosing, 265
methioclopramide, 214
mianserin
in bulimia nervosa treatment, 228, 229
drug augmentation, 14
in obsessive-compulsive disorder treatment, 181
mineral supplements, in bipolar disorder
prophylaxis, 42
Mini-Mental State Examination (MMSE), 298, 306
overview, 300
mirtazapine, 2, 149
in acute bipolar depression treatment, 32
in posttraumatic stress disorder treatment, 125
in social anxiety disorder treatment, 141, 141–2, 152, 155
versus placebo, 141–2
monoamine hypothesis of depression, 1
monoamine oxidase A, inhibition, 309
monoamine oxidase B
inhibition, 309
localization, 309
monoamine oxidase inhibitors (MAOIs), 1, 308
in acute bipolar depression treatment, 32
in attention-deficit hyperactivity disorder
treatment, 269, 273
in bulimia nervosa treatment, 222, 223, 233
drug interactions, 222, 322
limitations, 15
in panic disorder treatment, 108, 109
in posttraumatic stress disorder treatment, 125, 127
response, sex differences, 9
side-effects, 222, 273
in social anxiety disorder treatment, 139–41, 148, 154–5
trials, 8–9
see also reversible inhibitors of monoamine
oxidase (RIMAs)
muscarinic receptor agonists, 293
nadolol, in attention-deficit hyperactivity disorder
treatment, 277
nalbuphine, in acute bipolar depression treatment, 214
in binge-eating disorder treatment, 234, 237
in bulimia nervosa treatment, 228
in posttraumatic stress disorder treatment, 129
National Comorbidity Survey (SC), 1, 137
National Institute of Clinical Excellence (UK), 308–5, 306
guidelines, 306
National Institute of Neurological and
Communicative Disorders and Stroke and
the Alzheimer’s Disease and Related
Disorders Association (NINCDS-ADRDA)
(350), 308
criteria, 300, 311
National Institutes of Mental Health (NIMH) (US), 6, 17

National Institutes of Mental Health Global Obsessive-Compulsive Scale (NIMH-OCS), 167, 174, 184

sertraline studies, 170

NDRIs (norepinephrine (noradrenaline) dopamine reuptake inhibitors), 228

nefazodone, 2

in posttraumatic stress disorder treatment, 126

neuroendocrine system disturbances, in posttraumatic stress disorder, 122

neuroleptic agents

in acute bipolar depression treatment, 31

in acute mania treatment, 25–7

and Alzheimer’s disease, 292

in bipolar disorder prophylaxis, 39, 40–1, 44

Neuropsychiatric Inventory (NPI), 295, 301

neurotransmitter disturbances

in generalized anxiety disorder, 89–90

in posttraumatic stress disorder, 122

neurotransmitters, antidepressant effects on, 2, 271

nicotine

in Alzheimer’s disease treatment, 293–4

in attention-deficit hyperactivity disorder treatment, 278

nicotinic dysregulation, and attention-deficit hyperactivity disorder, 277–8

nicotinic receptor agonists, 293, 294

NIMH (National Institutes of Mental Health) (US), 6, 17

NIMH-OCS see National Institutes of Mental Health Global Obsessive-Compulsive Scale (NIMH-OCS)

NINCDS-ADRDA see National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) (US)

NMDA see N-methyl-D-aspartate (NMDA)

non-generalized anxiety disorder characteristics, 137

treatment, 159

non-serotonergic antidepressants, versus serotonin reuptake inhibitors, 168–9

non-stimulants, in attention-deficit hyperactivity disorder treatment, 268–74

norepinephrine, 1, 2

norepinephrine (noradrenaline) dopamine reuptake inhibitors (NDRIs), in bulimia nervosa treatment, 228

norepinephrine, 1

norepinephrine (noradrenaline) dopamine reuptake inhibitors (NDRIs), in bulimia nervosa treatment, 228

Noritrixtine

in attention-deficit hyperactivity disorder treatment, 269, 270, 271

axis II personality disorder studies, 8
effectiveness, 7

versus clomipramine, 167, 168

NSRIs (noradrenergic specific reuptake inhibitors), 274–5

obsessive-compulsive disorder (OCD)

age of onset, 165

comorbidity, 165

costs, 165

with depression, 167–8, 181

diagnosis, issues, 165–6

diagnostic criteria, 165

etiology, 166

expert consensus guidelines, 178

maintenance treatment, 186

pharmacotherapy
dosage issues, 178–80, 186–7
dose-titration strategies, 180
duration, 182–7
evidence-based, 165–93

first-line, 166–82

long-term, 182, 186–7

meta-analyses, 173

response rates, 172

trials, 166

withdrawal effects, 183–4

prevalence, 165

rating scales, 165

relapse, 183–4

prevention, 184–6

sex differences, 165

studies

see also serotonin–norepinephrine (noradrenaline) reuptake inhibitors (SNRIs)
noradrenergic neurotransmission, 257

noradrenergic specific reuptake inhibitors (NSRIs), in attention-deficit hyperactivity disorder treatment, 274–5

noradrenergic system, 206
disturbances, 89

norepinephrine, 1, 2

norepinephrine (noradrenaline) dopamine reuptake inhibitors (NDRIs), in bulimia nervosa treatment, 228

nortriptyline

in attention-deficit hyperactivity disorder treatment, 269, 270, 271

axis II personality disorder studies, 8
effectiveness, 7

versus clomipramine, 167, 168

NSRIs (noradrenergic specific reuptake inhibitors), 274–5

obsessive-compulsive disorder (OCD)

age of onset, 165

comorbidity, 165

costs, 165

with depression, 167–8, 181

diagnosis, issues, 165–6

diagnostic criteria, 165

etiology, 166

expert consensus guidelines, 178

maintenance treatment, 186

pharmacotherapy
dosage issues, 178–80, 186–7
dose-titration strategies, 180
duration, 182–7
evidence-based, 165–93

first-line, 166–82

long-term, 182, 186–7

meta-analyses, 173

response rates, 172

trials, 166

withdrawal effects, 183–4

prevalence, 165

rating scales, 165

relapse, 183–4

prevention, 184–6

sex differences, 165

studies

see also serotonin–norepinephrine (noradrenaline) reuptake inhibitors (SNRIs)
noradrenergic neurotransmission, 257

noradrenergic specific reuptake inhibitors (NSRIs), in attention-deficit hyperactivity disorder treatment, 274–5

noradrenergic system, 206
disturbances, 89

norepinephrine, 1, 2

norepinephrine (noradrenaline) dopamine reuptake inhibitors (NDRIs), in bulimia nervosa treatment, 228

nortriptyline

in attention-deficit hyperactivity disorder treatment, 269, 270, 271

axis II personality disorder studies, 8
effectiveness, 7

versus clomipramine, 167, 168

NSRIs (noradrenergic specific reuptake inhibitors), 274–5

obsessive-compulsive disorder (OCD)

age of onset, 165

comorbidity, 165

costs, 165

with depression, 167–8, 181

diagnosis, issues, 165–6

diagnostic criteria, 165

etiology, 166

expert consensus guidelines, 178

maintenance treatment, 186

pharmacotherapy
dosage issues, 178–80, 186–7
dose-titration strategies, 180
duration, 182–7

evidence-based, 165–93

first-line, 166–82

long-term, 182, 186–7

meta-analyses, 173

response rates, 172

trials, 166

withdrawal effects, 183–4

prevalence, 165

rating scales, 165

relapse, 183–4

prevention, 184–6

sex differences, 165

studies
population-change effects, 172
resources, 166

treatment-resistant
drug augmentation, 188
pharmacotherapy, 187–92
strategies, 187–8, 191–2
treatment-response predictors, 187
odds ratio (OR), 149

OPC (olanzapine-fluoxetine combination), 31, 32
olanzapine, 23, 125
in acute bipolar depression treatment, 31
in acute mania treatment, 26–7, 28
in anorexia nervosa treatment, 207, 209
in bipolar disorder prophylaxis, 39–40
drug augmentation, 15, 191
intramuscular, 62–3
maintenance treatment, 63
meta-analyses, 63
monotherapy, 31, 32
in posttraumatic stress disorder treatment, 129
in resistant schizophrenia treatment, 73
in schizophrenia treatment, 61–3, 71–2
side-effects, 26–7, 39–60
in social anxiety disorder treatment, 146
versus atypical antipsychotics, 63
versus conventional antipsychotics, 62
versus placebo, 61–2
versus risperidone, 59, 63
olanzapine-fluoxetine combination (OPC), in acute bipolar depression treatment, 31, 32
omega-3 fatty acids, in bipolar disorder prophylaxis, 42
ondansetron, in bulimia nervosa treatment, 229, 230
opiate antagonists
in anorexia nervosa treatment, 214, 216
in bulimia nervosa treatment, 228
opioid peptide system, 214
OR (odds ratio), 149
oxcarbazepine
in acute bipolar depression treatment, 31
in acute mania treatment, 25
2-oxo-1-pyrrolidine acetamide see piracetam

P450 enzymes, 323, 336
CYP1A2, induction, 331–5
CYP2D6, 331–5
inhibition, 337
CYP2E1, induction, 331–5
CYP3A4, induction, 331–5
in drug metabolism, 328, 331
induction, 331–5
inhibition, 337

panic disorder (PD)
age of onset, 106
avoidance strategies, 107
comorbidity, 105, 106–7
definition, 105
diagnosis, 105–7
differential diagnosis, 106
etiology, 106
pharmacotherapy, 105–17
approaches, 105, 108–12
dosage issues, 108
first-line, 112–14, 117
long-term effects, 114–15
meta-analyses, 111–12
posttest studies, 113
with psychotherapy, 107
treatment duration, 114–15, 116
prevalence, 105, 106
psychotherapy, treatment duration, 116
relapse prevention, 115
study resources, 105
symptoms, 105
treatment
combination, 110–11, 116
cost factors, 116–17
options, 107, 116–17
short-term, 116
treatment-resistant, pharmacotherapy, 115, 116
versus anxiety disorders, 106
PANSS (Positive and Negative Symptom Scale), 58, 209
parkinsonism, 63, 69, 72
Parkinson’s disease, 291, 309
paroxetine, 1
in acute bipolar depression treatment, 29, 31, 32
in binge-eating disorder treatment, 237
dose–response relationships, 179
drug-switching studies, 13
effectiveness, 4
efficacy, 92, 96, 99
in generalized anxiety disorder treatment, 91–2
treatment duration, 97
in obsessive-compulsive disorder treatment, 171, 175–6
P450 enzyme inhibition, 337
in panic disorder treatment, 109, 111–12
platelet binding, 89
paroxetine (cont.)
in posttraumatic stress disorder treatment, 125, 126
relapse rates, 184–6
in social anxiety disorder treatment, 142–3, 156, 158
versus citalopram, 90
versus escitalopram, 91, 97–8
versus placebo, 91–2, 96, 142–3, 171
versus venlafaxine, 181–2
withdrawal effects, 183–4
patient compliance see adherence
Patient Impression of Change–Social Phobia Scale, 141
Paxil see paroxetine
PD see panic disorder (PD)
PDS (Progressive Deterioration Scale), 301
pemoline see magnesium pemoline
perhenazine, with amitriptyline, 322
P-gp see P-glycoprotein (P-gp)
pharmacokinetics
drug interactions, 321–2
mechanisms, 327–36
principles, 324–7
pharmacotherapy
acute bipolar depression, 28–35
acute mania, 23–8
Alzheimer’s disease, 290–314
duration, 306–7
treatment-resistant, 313–14
attention-deficit hyperactivity disorder, 255–79
duration, 278–9
treatment-resistant, 282–4
bipolar disorder prophylaxis, 35–44
eating disorders, 204–45
efficacy, 292
effectiveness, 292
efficacy, 292
generalized anxiety disorder, 88–99
duration, 97–8
treatment-resistant, 98
major depressive disorder, 3–10
duration, 10–12
treatment-resistant, 12–15
obsessive-compulsive disorder, 163–93
duration, 182–7
treatment-resistant, 187–92
panic disorder, 105–17
duration, 114–15
treatment-resistant, 115
posttraumatic stress disorder, 121–30
duration, 127–8
treatment-resistant, 128–9
with psychotherapy, 98, 107, 115, 230–1
schizophrenia, 56–78
treatment-resistant, 72–8
social anxiety disorder, 137–60
duration, 155–7
treatment-resistant, 157–8
phenelzine, 8–9, 125, 273
in bulimia nervosa treatment, 222
in panic disorder treatment, 109, 115
in posttraumatic stress disorder treatment, 125, 127
in social anxiety disorder treatment, 139–41, 152, 153, 154–6
versus fluoxetine, 168, 171
versus moclobemide, 141
р-phenylalanine, 278
phenylpropanolamines, 272
phenynitin, in bulimia nervosa treatment, 228
pheochromocytoma, 106
pimozide, 78
in anorexia nervosa treatment, 207
drug augmentation, 190
pindolol
in attention-deficit hyperactivity disorder treatment, 277
drug augmentation, 190
in social anxiety disorder treatment, 158
piracetam
activity, 311
in Alzheimer’s disease treatment, 311
cognitive impairment studies, 311
indications, 311
structure, 311
plasma drug concentration, steady-state, 326
platelets
benzodiazepine binding sites, 89
binding, 89
polypharmacy
in acute mania treatment, 28
in bipolar disorder prophylaxis, 28, 43–4
evidence-based, 22
population change, effects on
obsessive-compulsive disorder studies, 172
Positive and Negative Symptom Scale (PANSS), 58, 209
POSITRON EMISSION TOMOGRAPHY (PET), ATTENTION-DEFICIT HYPERACTIVITY DISORDER STUDIES, 255–6
POSTMENOPAUSAL WOMEN, HORMONE REPLACEMENT THERAPY, 312
POSTTRAUMATIC STRESS DISORDER (PTSD)
COMORBIDITY, 121
COSTS, 121
DETECTION, 121
DIAGNOSIS, 121–2
MAINTENANCE TREATMENT, 127–8
NEUROTRANSMITTER DYSREGULATION, 122
PHARMACOTHERAPY
DOSE ISSUES, 127
DURATION, 127–8
EFFECTIVENESS, 125
EVIDENCE-BASED, 121–30
FIRST-LINE, 125–7
STUDY RESOURCES, 122
TRIALS, 122–5
PREVAILENCE, 121
RECOGNITION, 121
STUDY RESOURCES, 122
SUBTYPES, 121
TREATMENT-RESISTANT
DRUG AUGMENTATION, 128
PHARMACOTHERAPY, 128–9
PEGABALIN, 89
EFFICACY, 99
IN GENERALIZED ANXIETY DISORDER TREATMENT, 94–5
VERSUS PLACEBO, 94
PREMEDLINE, SEARCHES, 139
PREGNANCY, 290
ETIOLOGY, 290
PROGESTERONE, TRIALS, 312
PROGRESSIVE DETERIORATION SCALE (PDS), 301
PROKINETIC AGENTS, IN ANOREXIA NERVOSA TREATMENT, 211–4, 215
PROLACTIN
ANTIPSYCHOTIC EFFECTS, 77
ELEVATED LEVELS, 77
PREGNANCY
ANTS POSTTRAUMATIC STRESS DISORDER TREATMENT, 127
IN GENERALIZED ANXIETY DISORDER TREATMENT, 96
IN NON-GENERALIZED SOCIAL ANXIETY DISORDER TREATMENT, 159
IN PANIC DISORDER TREATMENT, 107
IN POSTTRAUMATIC STRESS DISORDER TREATMENT, 129
PROTEIN BINDING
ALTERED, 329–31
DISPLACEMENT INTERACTIONS, 330
IN DRUG INTERACTIONS, 327
REVERSIBILITY, 330
PROTHIAPILINE, IN ATTENTION-DEFICIT HYPERACTIVITY DISORDER TREATMENT, 270
PROSTATE-SPECIFIC FLUORESCENCE
PSYCHIATRY, DRUG INTERACTIONS, 321–3
PSYCHINFO, 139
SEARCHES, 166
PSYCHLIT, 2
SEARCHES, 122
PSYCHOACTIVE DRUGS
DRUG INTERACTIONS, 320–1, 332
METABOLISM, 331
AND PANIC DISORDER, 106
PROTEIN BINDING, 327
PSYCHODYNAMIC PSYCHOTHERAPY, IN PANIC DISORDER TREATMENT, 107
PSYCHOSIS, STIMULANT-INDUCED, 284
PSYCHOTHERAPY
IN ANOREXIA NERVOSA TREATMENT, 211
INTERPERSONAL, 231
IN OBSESSIVE-COMPulsive DISORDER TREATMENT, 174–5
WITH PHARMACOTHERAPY, 98, 107, 115, 230–1
SUPPORTIVE, 230–1
IN TREATMENT-RESISTANT SOCIAL ANXIETY DISORDER, 158
SEE ALSO BEHAVIOR THERAPY; COGNITIVE-BEHAVIORAL THERAPY (CBT); EXPOSURE THERAPY
PSYCHOTROPICS, IN GENERALIZED ANXIETY DISORDER TREATMENT, 94–7
PTSD SEE POSTTRAUMATIC STRESS DISORDER (PTSD)
Q STATISTIC, 152
QT INTERVAL PROLONGATION, ANTIPOSYCHOTIC-INDUCED, 78
QUALITY OF LIFE, 301
QUATRIPIpine
IN ACUTE MANIA TREATMENT, 27
DRUG AUGMENTATION, 193
MAINTENANCE STUDIES, 65
META-ANALYSES, 65
IN POSTTRAUMATIC STRESS DISORDER TREATMENT, 129
IN RESISTANT SCHIZOPHRENIA TREATMENT, 73–4
IN SCHIZOPHRENIA TREATMENT, 65–6
© Cambridge University Press
www.cambridge.org
quetiapine (cont.)
versus atypical antipsychotics, 65
versus conventional antipsychotics, 64–5
versus placebo, 63–4

random effects model, 152
versus fixed-effects model, 150
randomized controlled trials (RCTs), bias issues, 27
reboxetine, in panic disorder treatment, 109
recombinant human growth hormone, 218, 219
relapse, concept of, 183
Remeron see mirtazapine
Reminyl see galantamine
Research Unit on Pediatric Psychopharmacology Anxiety Study Group, 159
reserpine, depression induction, 3
reversible inhibitors of monoamine oxidase (RIMAs), 273
development, 2
effectiveness, 5–6
in major depressive disorder treatment, 5–6
in posttraumatic stress disorder, 125
in social anxiety disorder treatment, 141–2, 155
RIMAs see reversible inhibitors of monoamine oxidase (RIMAs)
risperidone, 23
in acute bipolar depression treatment, 31
in acute mania treatment, 26
in anorexia nervosa treatment, 207–9
in bipolar disorder prophylaxis, 40
drug augmentation, 190–1
injection, long-acting, 58–9
maintenance treatment, 60
meta-analyses, 60–1
in posttraumatic stress disorder treatment, 129
in resistant schizophrenia treatment, 72–3
in schizophrenia treatment, 57, 72
relapse rates, 60
side-effects, 59–60
versus atypical antipsychotics, 59–60
versus cognitive-behavioral therapy, 71
versus conventional antipsychotics, 58
versus olanzapine, 59, 63
versus placebo, 57–8
Ritalin see methylphenidate
Ritalin LA
in attention-deficit hyperactivity disorder treatment, 266–7
dosage issues, 266
versus placebo, 266–7
rivastigmine
in Alzheimer’s disease treatment, 294, 297
benefits, 298
risk factors, 299
cost-effectiveness, 304–5
in dementia with Lewy bodies treatment, 295
dosage issues, 295, 303
drug interactions, 304
side-effects, 302
titration schemes, 302
trials, 301
versus donepezil, 302, 303
versus placebo, 301
Rokin see EGb 761
saccadic eye movement velocity, 89
St. John’s wort, 329
SARIs (serotonin–2 antagonist/reuptake inhibitors), 228–30
schizophrenia, 27, 40
first-episode, 72
pharmacotherapy evidence-based, 56–78
first-line, 57–72
prepsychotic period, 71–2
relapse rates, 60
special populations, 71–2
treatment-resistant, pharmacotherapy, 72–8
SCID-IV (Structured Clinical Interview for DSM-IV Axis IV), 121–2
SDS (social disability scale), 140
selective serotonin reuptake inhibitors (SSRIs), 1, 89
advantages, 4–5
in anorexia nervosa treatment, 211, 212
and attention-deficit hyperactivity disorder, 273–4
with benzodiazepines, 110, 114, 115
in binge-eating disorder treatment, 234–7
in bulimia nervosa treatment, 222–7, 233, 236
dose–response relationship, 3–4
drug interactions, 322–3
drug switching, 187–8
studies, 13
effectiveness, 4, 7
efficacy, 4, 99
in generalized anxiety disorder treatment, 90–3, 96–7
in major depressive disorder treatment, 3–5, 15
in obsessive-compulsive disorder treatment, 166, 169, 172, 176–8
response rates, 173
in panic disorder treatment, 108, 109, 110, 111–12, 114
platelet binding, 89
in posttraumatic stress disorder treatment, 122, 125–7, 130
response, sex differences, 9
side-effects, 127, 176–8
in social anxiety disorder treatment, 142–5, 148, 149, 151, 152, 153–4
trials, 8–9
with tricyclic antidepressants, 274
versus clomipramine, 173–4, 176, 177, 181
versus placebo, 172, 179
versus tricyclic antidepressants, 110, 111–12, 113–14
selegiline
in Alzheimer’s disease treatment, 308–9
mechanisms, 308
senile dementia
and Alzheimer’s disease compared, 290
use of term, 290
Sequenced Treatment Alternatives to Relieve Depression (STAR*D), 6
study goals, 16–17
serotonergic system, 109, 206
serotonin, 1, 271
and eating disorders, 206
and generalized anxiety disorder, 89
in obsessive-compulsive disorder, 166, 181
and posttraumatic stress disorder, 122
serotonin-norepinephrine (noradrenaline) reuptake inhibitors (SNRIs)
efficacy, 99
in social anxiety disorder treatment, 154
serotonin receptor antagonists, 1
serotonin reuptake inhibitors (SSRIs)
in acute bipolar depression treatment, 32, 33
drug augmentation, 188, 190–1
drug switching, 187–8
in obsessive-compulsive disorder treatment, 166–9
with depression, 181
direct comparisons, 173–6
long-term, 182
meta-analysis, 173
versus psychotherapies, 174–5
versus nonserotonergic antidepressants, 168–9
see also selective serotonin reuptake inhibitors (SSRIs)
serotonin-2 antagonist/reuptake inhibitors (SARIs), in bulimia nervosa treatment, 228–30
sertraline
maintenance studies, 67–8
meta-analyses, 68
in schizophrenia treatment, 67–8
suspended in UK, 78
versus conventional antipsychotics, 67
versus placebo, 67
sertraline, 1
in acute bipolar depression treatment, 33
axis II personality disorder studies, 8
in binge-eating disorder treatment, 237
dose–response relationships, 179–80
drug augmentation, 14
drug-switching studies, 13
effectiveness, 4
efficacy, 96, 99
in generalized anxiety disorder treatment, 92–3
in obsessive-compulsive disorder treatment, 170, 175–6, 182
long-term, 183
in panic disorder treatment, 109
in posttraumatic stress disorder treatment, 125, 126, 128
response, sex differences, 9
in social anxiety disorder treatment, 144, 148, 156
versus citalopram, 90
versus clomipramine, 174–5
versus desipramine, 181
versus exposure therapy, 144
versus placebo, 92–3, 144, 170
Sezary syndrome, 190–1
senile dementia
sexual dysfunction, risperidone-induced, 59, 77
Sheehan Disability Scale, 143, 145, 172
sick sinus syndrome, 304
sleep disturbances, stimulant-induced, 238–63
smoking, and Alzheimer’s disease, 293–4
smoking risk, and attention-deficit hyperactivity disorder, 277
SNAP rating scale, 268–9
SNRIs see serotonin–norepinephrine (noradrenaline) reuptake inhibitors (SNRIs)
social anxiety disorder
age of onset, 137
characteristics, 137
comorbidity, 154, 157
diagnostic criteria, 137
effects, 137
meta-analyses, 146–52
Blanco et al., 151–2, 153
Fedoroff and Taylor, 149–51
Gould et al., 147–9
Van der Linden et al., 149
pharmacotherapy
drug selection criteria, 152–5
effect size, 148
evidence-based, 137–60
first-line, 139–55
future research, 155–7
placebo-controlled studies, 138
placebo, 137
positive effect size, 148
prevalence, 137–9
resources, 137–9
side-effects, 147–8
treatment, 137
treatment outcomes
long-term, 148–9
management, 158
non-adherence, 157
relapse, 156–7
sex differences, 148, 150
treatment duration, 155–7
trials, 139–46
pharmacotherapy, 157–8
psychotherapy, 158
psychopharmacology, 157–8
see also generalized anxiety disorder (GAD); non-generalized anxiety disorder
social disability scale (SDS), 140
social phobia see social anxiety disorder
Social Phobia Inventory (SPIN), 146
SPT (supportive psychotherapy), 230–1
SRIs see serotonin reuptake inhibitors (SRIs)
SSRIs see selective serotonin reuptake inhibitors (SSRIs)
STAI (State and Trait Anxiety Inventory), 140
STAR*D see Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
State and Trait Anxiety Inventory (STAI), 140
stimulants
analog classroom paradigms, 265
in attention-deficit hyperactivity disorder
treatment, 257–68
delivery systems, 265
disadvantages, 268–9
drug holidays, 265
long-term effects, 264–5
new generation, 265–8
side-effects, 258–65
structure, 257
and substance abuse, 264, 268–9
versus tricyclic antidepressants, 270–1
stress, and bipolar disorder, 22
Structured Clinical Interview for DSM-IV Axis IV (SCID-IV), 121–2
subdural hematoma, 310
substance abuse
and attention-deficit hyperactivity disorder, 264
and bipolar disorder, 22
and social anxiety disorder, 154
and stimulants, 268–9
sudden death, children, 276–7
suicidality, 171
suicide
and bipolar disorder, 22
lithium prophylaxis, 37–8
sulpiride
in anorexia nervosa treatment, 207
drug augmentation, 190
sumatriptan, and treatment-resistant obsessive-compulsive disorder, 191
supportive psychotherapy (SPT), in bulimia nervosa treatment, 230–1
tachyphylaxis, 265
tacrine
in Alzheimer’s disease treatment, 294
side-effects, 294
Tanakan see Egb-761
tardive dyskinesia (TD), 40
TCAs see tricyclic antidepressants (TCAs)
TD (tardive dyskinesia), 40
tetrahydrocannabinol (THC)
in anorexia nervosa treatment, 214–16
side-effects, 216
Index

Texas Medication Algorithm Project (TMAP), 6, 17
thalamus, 89
THC see tetrahydrocannabinol (THC)
thioridazine, 78
D-threo-methylphenidate see dexmethylphenidate
thrombocytes see platelets
tic disorders, 190, 271
stimulant-induced, 264
TMAP (Texas Medication Algorithm Project), 6, 17
topiramate, 25
in acute bipolar depression treatment, 30
in binge-eating disorder treatment, 238, 239
in bipolar disorder prophylaxis, 38
in posttraumatic stress disorder treatment, 128–9
Tourette’s syndrome, 190, 275, 276
transcranial magnetic stimulation, 191
tranylcypromine, 273
in acute bipolar depression treatment, 32
transdine, 1
in bulimia nervosa treatment, 228–30
effectiveness, 5
in posttraumatic stress disorder treatment, 126
versus imipramine, 95
tricyclic antidepressants (TCAs), 1
in acute bipolar depression treatment, 32
in anorexia nervosa treatment, 209–11
in attention-deficit hyperactivity disorder treatment, 269–72
with benzodiazepines, 115
in binge-eating disorder treatment, 234, 235
and bipolar disorder, 41
in bulimia nervosa treatment, 219–22
drug augmentation, 16
effectiveness, 7
effects on cardiovascular system, 271–2
efficacy, 4
and elderly, 10
in generalized anxiety disorder treatment, 95
limitations, 15, 99
in panic disorder treatment, 108, 109, 110, 111–12
in posttraumatic stress disorder treatment, 125, 127
response, sex differences, 9
with selective serotonin reuptake inhibitors, 274
side-effects, 127, 211, 271–2
tolerance, 7
trials, 8–9
versus selective serotonin reuptake inhibitors, 110, 111–12, 113–14
versus stimulants, 270–1
trifluoperazine
efficacy, 96
in generalized anxiety disorder treatment, 96
triiodothyronine, 14
L-tryptophan, in obsessive-compulsive disorder treatment, 181
L-tyrosine, 278
UGTs see uridine glucuronyltransferases (UGTs)
unipolar disorder
diagnosis, 12
prevalence, 22
recurrence, 11
uridine glucuronyltransferases (UGTs), 311, 336
in drug metabolism, 328
valproate, 23
in acute bipolar depression treatment, 29–30
in acute mania treatment, 23–5
antidepressant activity, 30
in bipolar disorder prophylaxis, 38, 39–40, 43
drug clearance, 326–7
in posttraumatic stress disorder treatment, 128–9
vascular dementia, 291, 294
pharmacotherapy, 295–8
venlafaxine, 2, 89, 274
in acute bipolar depression treatment, 32, 33
dose–response relationship, 94
drug switching, 187–8
drug-switching studies, 13
effectiveness, 5, 15
efficacy, 96, 99
in generalized anxiety disorder treatment, 93–4
treatment duration, 97
in obsessive-compulsive disorder treatment, 181–2
in posttraumatic stress disorder treatment, 126
in social anxiety disorder treatment, 145, 154
versus placebo, 93, 96, 145
versus pregabalin, 94–5
verapamil, 27
vigabatrin, in posttraumatic stress disorder treatment, 128–9

© Cambridge University Press
www.cambridge.org
vitamin E
in Alzheimer’s disease treatment, 309–10
definition, 309
occurrence, 309
supplements, 309
versus placebo, 309–10
vitamin supplements, in bipolar disorder prophylaxis, 42
war veterans, posttraumatic stress disorder, 125
weight gain
and anorexia nervosa, 207
antipsychotic-induced, 76–7
and binge-eating disorder, 204–5
and bulimia nervosa, 204
olanzapine-induced, 72
risperidone-induced, 59
sertindole-induced, 68
see also eating disorders (EDs)
Wellbutrin see bupropion
WHO (World Health Organization), 1
World Council on Anxiety, 178
World Health Organization (WHO), 1
Writing Group for the Women’s Health Initiative Investigators, 312
Yale–Brown Obsessive Compulsive Scale (Y-BOCS), 165, 167, 183, 188
citalopram studies, 172
clozapine studies, 174
fluvoxamine studies, 170
furoxamine studies, 169, 190
paroxetine studies, 171, 176, 182
quetiapine studies, 191
risperidone studies, 190
sertraline studies, 170
treatment-response studies, 187
venlafaxine studies, 182
Y-BOCS see Yale–Brown Obsessive Compulsive Scale (Y-BOCS)
yohimbine, effects on noradrenergic system, 89
zimelidine, 169
in panic disorder treatment, 111–12
zinc deficiency, and anorexia nervosa, 216
zinc sulfate, 216
zinc supplementation, in anorexia nervosa treatment, 216
ziprasidone, 27
in acute bipolar depression treatment, 31
intramuscular, 66
maintenance studies, 66
meta-analyses, 66–7
QT interval prolongation, 78
in schizophrenia treatment, 65–7
side-effects, 65
versus conventional antipsychotics, 66
versus placebo, 65–6
Zoloft see sertraline
zonisamide, 31